The FDA has approved the monoclonal antibody spesolimab (Spevigo) as the first treatment for generalized pustular psoriasis (GPP), Boehringer Ingelheim announced. The approval stipulates use of the ...

The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.

Spevigo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling. The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment ...

Aaron Farberg, MD, and Mark G. Lebwohl, MD, discuss the relapsing nature of generalized pustular psoriasis and how the difficulty in diagnosing the disease affects outcomes for patients. Ryan ...

INGELHEIM, Germany--(BUSINESS WIRE)--Today, at the 25 th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab ...

Aaron Farberg, MD, and Mark G. Lebwohl, MD, discuss the common comorbidities seen in patients with generalized pustular psoriasis (GPP) and some potential future developments in the management of GPP.

Localized pustular psoriasis is a term that refers to a limited area of small pus-filled blisters on your skin, typically on your hands or feet. It is distinct from generalized pustular psoriasis (GPP ...

The US Food and Drug Administration (FDA) has approved the biologic agent spesolimab (Spevigo) for the treatment of flares in adults with generalized pustular psoriasis (GPP), the company has ...

Please provide your email address to receive an email when new articles are posted on . Imsidolimab yielded a response rate of 75% at 16 weeks in patients with generalized pustular psoriasis. No ...

Imsidolimab is a humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor. Treatment with imsidolimab led to significant clearance of pustulation, erythema, and scaling in ...

Erosive pustular dermatosis (EPD) is a chronic inflammatory skin disorder predominantly affecting the scalp of older individuals, often in areas of pre-existing actinic damage and androgenetic ...

“EFFISAYIL™ 2 is the first and largest multinational randomized clinical trial to evaluate a treatment for the prevention of GPP flares,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, ...